FDA Progress Could Send This Biotech Stock Soaring To New Heights
Key takeaways
- FDA Progress Could Send This Biotech Stock Soaring To New Heights Jabran Kundi Fri, July 3, 2026 at 8:40 PM GMT+7 2 min read VERA Vera Therapeutics Inc.
- Earlier on June 2, Rami Katkhuda from Life Sci Capital maintained a Buy rating on Vera Therapeutics Inc.
- In addition, the analyst also pointed to strong data from an earlier Phase IIb eGFR study and noted atacicept is currently under priority review for accelerated approval.
FDA Progress Could Send This Biotech Stock Soaring To New Heights Jabran Kundi Fri, July 3, 2026 at 8:40 PM GMT+7 2 min read VERA Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 11, Wells Fargo reiterated its Buy rating on Vera Therapeutics Inc. (NASDAQ:VERA) stock, along with a price target of $70.
Earlier on June 2, Rami Katkhuda from Life Sci Capital maintained a Buy rating on Vera Therapeutics Inc. (NASDAQ:VERA) and set a target price of $90 on the stock. The positive analyst sentiment is driven by the strong potential of the company's lead drug candidate, atacicept, for treating IgA nephropathy. The company's agreement with the FDA, announced on June 2, 2026, allows VERA to analyze key kidney function data from its Phase III ORIGIN 3 study earlier than expected. Moreover, if the trial results are positive, the firm could apply for full FDA approval of its lead drug, atacicept, in the fourth quarter of 2026.
In addition, the analyst also pointed to strong data from an earlier Phase IIb eGFR study and noted atacicept is currently under priority review for accelerated approval. The drug may be approved for a broader group of IgA nephropathy patients, which could expand its market opportunity, noted the analyst.